Ryman Healthcare Limited
RHCGF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -4.29 | -0.09 | 0.03 |
| FCF Yield | 13.84% | 24.07% | 15.13% | 17.73% |
| EV / EBITDA | -142.35 | -89.65 | 8.21 | 4.95 |
| Quality | ||||
| ROIC | -2.15% | 0.02% | -0.20% | 0.02% |
| Gross Margin | 100.00% | -0.21% | -3.53% | 0.36% |
| Cash Conversion Ratio | – | – | 2.11 | 0.77 |
| Growth | ||||
| Revenue 3-Year CAGR | 8.42% | 8.90% | 7.38% | 6.07% |
| Free Cash Flow Growth | -37.71% | 122.50% | -7.91% | 61.39% |
| Safety | ||||
| Net Debt / EBITDA | -61.78 | -49.82 | 5.06 | 3.25 |
| Interest Coverage | -0.85 | -1.38 | -0.16 | 0.06 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 273.21 | 39.67 | 19.08 |
| Cash Conversion Cycle | 72.31 | 325.25 | 409.61 | 459.41 |